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Human mesenchymal stem cells creating
an immunosuppressive environment and
promote breast cancer in mice
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Stefan Przyborski2, Nebojsa Arsenijevic1, Miodrag L. Lukic1 & Miodrag Stojkovic1
1Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, Kragujevac, Serbia,
2School of Biological and Biomedical Sciences, Durham University, Durham, UK, 3Laboratory for Experimental Hematology and
Stem Cells, Institute for Medical Research, University of Belgrade, Belgrade, Serbia.
Humanmesenchymal stem cells (hMSC) can home to tumor sites and promote tumor growth. The effects of
hMSC on tumor growth are controversial and involvement of hMSC in tumor immunology has not been
adequately addressed. Therefore, we investigated whether injection of hMSC affects tumor appearance,
growth and metastasis, and anti-tumor immunity in an experimental animal model of metastatic breast
cancer. Injection of hMSC in BALB/c mice bearing mammary carcinoma promoted tumor growth and
metastasis, which was accompanied by lower cytotoxic activity of splenocytes, NK cells and CD81 T cells in
vitro. Tumor-bearing mice that received hMSC had significantly lower percentages of CD31NKp461
NKT-like, higher percentages of CD41Foxp31 T cells, increased serum levels of Th2 and decreased serum
levels of Th1 cytokines, and significantly higher number of CD41 cells expressing IL-10. These results
demonstrate that immunosuppressive environment created by hMSC promoted breast tumor growth and
metastasis in mice.
M
esenchymal stem cells (MSC) have been identified in the bonemarrow, connective tissue and peripheral
blood as multipotent cells that proliferate in vitro as plastic adherent cells. These cells have the capacity
to differentiate into fibroblast, osteoblast, and adipocyte lineages1,2. It has been demonstrated that
human MSC, (hMSC) maintained under standard culture conditions are non-tumorigenic per se: however,
several reports indicate their capability to modulate tumor microenvironment thus having an impact on the
tumor behaviour3,4. Lin et al.5 demonstrated that MSC have exerted immune protection, and, in case of breast
cancer, they can support cancer growth6. AlsoMSC can contribute to the tumor growth and progression through
several mechanisms including their immunomodulatory effects. These effects depend on their basic character-
istics, time and method of administration in relation to pathological conditions7,8. As far as tumor modulation is
concerned, MSC can have both, stimulatory9 and suppressive effects10. Most specifically, in an experimental
model of breast cancer it has been shown that MSC may have both of the above effects. The intravenous
administration of MSC appears to effect tumor growth indirectly by modulating the immune microenvironment
before they act by direct interaction with tumor cells. It has been shown that MSC overexpressed IFN-b by
affecting STAT3 signaling pathway, however, ‘‘normal‘‘ MSC stimulated rather than suppresed 4T1 breast cancer
cells growth11.
MSC are generally thought to have immunosuppressive effects, which may be an important mechanism
through which MSC promote tumor growth or increase incidence of tumor formation also under in vivo
conditions They can impair the function of a variety of immune cells directly or by secreting different growth
factors possibly by inhibition of both, innate and adaptive immune cells12,13. However, the immunomodulatory
effects of MSC, if any, are not well understood within tumors. Djouad et al.14 reported that the immunosuppres-
sive action of MSC led to a higher incidence of melanoma formation in a mouse model. Evidence for the effect of
MSC on tumor immunity also comes from a clinical study15 which could be explained by the creation of
immunosuppressive milieu including shifting of immune responses fromTh1 to Th216 or induction of generation
and proliferation of regulatory T cells17. However, regulatory T cells (Tregs) are mostly immunosuppressive, and
have been shown to suppress effector T cell functions and autoimmunity18,19. They suppress T-cell responses by
acting directly or through the inhibition of antigen-presenting cells involving cell-to-cell contact, FasL/Fas, and
PD1/B7-H1-dependent processes, or secreted factors such as IL-10, TGF-beta, IL-27, and IL-3520–22. As a result,
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Tregs are considered to play a key role in the escape of cancer cells
from antitumor effector T cells23,24. Indeed, suppressing Treg has
been shown to be effective in enhancing the immune response of
host cells to cancer cells25,26. Although, the role and function of T
regulatory cells and induction of immunosuppression is well
accepted, there is still no conceivable data to explain the factors
and mediators which support the generation of T regulatory cells
during the process of malignancy. Olkhanud et al.27 have reported
that expansion of Tregs was induced without the involvement of
MSC showing that FoxP31Treg conversion from non-regulatory
CD41 T cells (non-Tregs) is mediated by a unique subset of regula-
tory B cells, designated tumor-evoked Bregs. On the other hand,
Selman et al.17 demonstrated that MSC induce the generation and
proliferation of regulatory T cells through the stimulation of IL-10
production and the release of HLA-G5. Also Patel et al.28 have
recently reported that hMSC under in vitro conditions can sup-
port breast cancer cells through TGF-b1 production and Treg
augmentation.
The aim of our study was to understand the mechanisms stimu-
lating tumor growth by the intravenous administration of hMSC
population cells derived from human peripheral blood. Here we
provide evidence that injection of heterogenous population of
hMSC may profundly afect mammary tumor growth by stimulating
hosts regulatory T cells and producing immunosupressive cytokines.
Results
hMSCmigrated in tumor and promoted breast tumor growth and
metastasis in dose dependent manner. To follow the biodistri-
bution of hMSC, we monitored the engraftment of hMSC by
polymerase chain reaction (PCR). Human CYP1A1 gene, which
does not show cross-reactivity to mouse DNA, was detected by
PCR analysis in tumor, blood, lymph node, spleen, liver, and lung
samples at 1st and 3rd day of the experiment, which suggested that
hMSChad potential tomigrate to variousmurine tissues (Fig. 1a). To
explore whether the transplanted hMSC present in tissues of mice at
35th day of the experiment, when themice were sacrificed, we used an
anti-human mitochondria antibody. As shown in Fig. 1c, hMSC
could retain for a long period of time in the liver of mice. On the
other hand, we did not observe the presence of hMSC in lung tissue
(Fig. 1d).
The 4T1:hMSC ratio had an impact on the incidence of tumor
growth (Figs. 1e–h). The highest incidence of tumor growth (Fig. 1e)
and the largest tumor volume (Figs. 1f–g) was seen in animals that
received 1 3 106 hMSC. Furthermore, as shown in Fig. 1h, linear
regression analysis showed a strong correlation (R2 5 0.865) between
the number of injected hMSC and tumor volume (Fig. 1g) suggesting
that number of injected hMSC in a dose-dependent manner affected
tumor growth. It appears that initial immunosuppresive effect of
hMSC facilitate the tumor growth increasing tumor load and capa-
city to metastase.
Semi-quantitative analysis of lung and liver tissue sections showed
that the incidence of lung and liver metastasis was significantly (P,
0.05) higher in tumor-bearing mice that received hMSC (Fig. 1i)
confirming that hMSC injection promoted both, tumor growth
and metastasis.
Injection of hMSC decreased cytotoxic capacity of CD81 T
lymphocytes and NK cells in tumor-bearing mice. There was a
significant increase (P , 0.05) in total number of splenocytes in
tumor bearing mice compared to mice from control group, but
cytotoxic capacity of these cells was significantly lower (P , 0.05)
than cytotoxic capacity of splenocytes derived from healthy animals
(Fig. 2a).
The total number of CD81 T lymphocytes (Fig. 2b) andNK cells in
the spleen (Fig. 2c) was not decreased after injection of hMSC (rep-
resentative dotplots that showed percentage of positive cells
expressed as mean 6 SEM, are provided in the supplemental
Figure S1) but there was a significant decrease in cytotoxic capacity
of both, CD81 T cells and CD32NKp461 NK cells derived from the
spleens of tumor-bearing mice treated with hMSC (P , 0.05 for
CD81 cells and P , 0.01 for NK cells).
The impact of hMSC on cellular make up of the spleen in tumor-
bearing mice. There was a significant decrease (P , 0.05) in the
percentage of CD31NKp461 NKT-like cells (Fig. 3a) in spleens
isolated from tumor-bearing hMSC-tretaed animals. Furthermore,
hMSC injection significantly (P , 0.05) decreased number of
CD31NKp461 NKT like cells in the spleen of tumor-bearing ani-
mals (Fig. 3b).
Also, cellular make-up of the spleen showed that there was a
significant difference in regulatory T cells. Both, the percentage
and total number of CD41Foxp31 T regulatory cells (Figs. 3e–f) were
significantly higher (P , 0.05) in spleens of tumor-bearing and
hMSC-treated animals which suggests that injection of hMSC sti-
mulated proliferation of T regulatory cells in tumor-bearing mice.
Injection of hMSC stimulated production of TGF-beta, IL-4 and
IL-10 but inhibited production of IFN-c in tumor bearing mice.
Tumor bearing mice expressed levels of IL-4 that were six times
higher than healthy control mice or mice inoculated with hMSC
cells alone. When hMSC were injected into tumor-bearing mice
the level of IL-4 was even higher reaching levels that were 10-fold
greater than that of healthy control mice (P, 0.05). Tumor bearing
mice injected with hMSC uniquely expressed high levels of IL-10 that
were nearly eight times greater those found in healthy control mice
(P, 0.01). Tumour bearing mice injected with hMSC expressed the
highest levels of TGF-ß which were nearly 4-fold higher than healthy
control mice, also significantly greater than the levels observed in
tumor-bearing mice or mice injected with hMSC cells alone (P ,
0.01). The high levels of IFN-gamma observed in tumor-bearing
mice (P , 0.05), nearly five times higher than seen in healthy mice
or those injected with hMSC alone, were halved in tumor-bearing
mice injected with hMSC (Fig. 4a).
The CD41 IL-101 cells were twice as abundant in tumor bearing
mice injected with hMSC than in mice injected with either cell type
alone (P, 0.05). The CD41 IFN-gamma1 cell population levels were
not significantly changed either by the presence of a tumor or by
injection of hPB-MSC cells (P . 0.05), the ratio between IL-10 and
IFN-c producing CD41 splenocytes was significantly higher (P ,
0.05) in tumor-bearing animals that received hMSC (Fig. 4b).
Discussion
It is known that MSC contribute to the maintenance and regenera-
tion of connective tissues29 and after systematic infusion, MSC
appear to engraft; this however seem to be dependent on the secre-
tion of paracrine signals in the tissues microenvironment which are
not as yet understood30. Solid tumor growth and invasion create a
microenvironment similar to that described in wound healing, which
also induces MSC to specifically migrate to the wound (or site of
inflammation)31,32. The evidence suggests that solid tumors generate
a wound-like environment on their periphery as they apply physical
and chemical stress to neighboring tissues. Tumors can therefore be
regarded as sites of tissue damage or, according to Dvorak, ‘‘wounds
that never heal’’31. Therefore, in the present study we examined
whether intravenously injection hMSC affects tumor growth in
experimental murine model of mammary carcinoma. With regard
ofMSC ability tomigrate, it does not seem that there is a specificity in
terms of organ homing as we were able to detect hMSC in tumor,
blood, lymph node, spleen, liver, and lung samples at 1st and 3rd days
of experiment, suggesting the exquisite selectivity of hMSC for
tumors. This corroborates with previous reports20,33,34 which have
shown that injected MSC engraft into tumor sites and can be used
www.nature.com/scientificreports
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Figure 1 | hMSCmigrated in tumor and promoted breast tumor growth andmetastasis. (a) Representative samples of PCR analysis showingmigration
and survival of hMSC. Human CYP1A1 gene, without cross-reactivity with mouse DNA, was detected by PCR analysis in tumor, blood, lymph node,
spleen, liver, and lung samples at 1st and 3rd day of experiment. Photomicrographs showing the presence humanmitochondrial marker in the tissues (b, c).
Positive signals were detected in human ESC control group (b) and in the livers of tumor-bearing mice that received hMSC (c), but no compelling
evidence of positively stained cells in lung mice from the same group (d). (e) Impact of 4T1: hMSC ratio on tumor growth. All animals received 2 3 104
4T1 cells. The highest incidence of tumor growth (e) and the largest tumor volume (f–g) was seen in tumor-bearing mice that received 1 3 106 hMSC.
There is a strong correlation between the number of injected hMSC and tumor volume (Fig. 1h; R2 5 0.865). (i) Semi-quantitative analysis of lung and
liver tissue sections. The incidence of lung and liver metastasis was significantly higher in tumor-bearing mice that received hMSC. Combined results of 3
experiments with total of 9 animals per group (mean 6 s.e.m.; *P , 0.05).
www.nature.com/scientificreports
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as effective gene delivery vehicles. Also, similar to others, we demon-
strated that hMSC may be present for a long period of time after
administration35. In the present study, hMSCwere persent at 35th day
of the experiment in the liver but not in the lung ofmice. This finding
is similar to previous reports which showed abbreviation of MSC
residence in the lung in diferent disease models, accompanied with
their persistence in the liver and spleen for long time after admin-
istration34,36. After evaluating hMSC tropism for tumor microenvir-
onments, we investigated the impact of hMSC on tumor growth and
metastasis. The reported effects of MSC on progression of primary
tumors have been both pro- and anti-tumorigenic, but variability in
these results, including ours, could be attributable to differences in
the sources of the MSC and the type of tumor model used for ana-
lysis7,31,37. We demonstrated that injection of hMSC promotes breast
tumor growth which was confirmed by the strong correlation be-
tween the number of injected hMSC and tumor volume. In addition,
hMSC promoted formation metastasis of tumors. By day 35, the
incidence of lung and liver metastasis was significantly higher in
tumor-bearing and hMSC-treated animals. This is similar to
Karnoub et al.32 who reported that MSC treatment can induce a
transient prometastatic effect on breast cancer cells but do not cor-
roborate other studies which reported that MSC suppress tumor
growth37 and metastasis38. However, MSC-mediated inhibitory
effects have only been observed in a few models including Kaposi
sarcoma37, and colon carcinoma39. Interestingly, systemic admin-
istration of mouse MSC had no effect growth 4T1 tumor40. Pro-
tumorigenic effects of MSC described in our study are consistent
with other studies14,41,42 and this phenomenon could be explained
by the role of direct cell-cell contact and/or by the effects of soluble
factors in MSC-mediated stimulation on tumor cell proliferation.
Therefore, to investigate potential mechanisms of tumor promotion
by MSC, we analyzed the cytotoxic capacity of splenocytes, and
Figure 2 | hMSC decreased cytotoxic capacity of CD81 T lymphocytes and NK cells in tumor-bearing mice. (a) There was a significant increase in total
number of splenocytes in tumor-bearing mice compared to mice from control group. The cytotoxic capacity of splenocytes derived from tumor-bearing
mice was significantly lower than cytotoxic capacity of splenocytes derived from healthy animals. Combined results of 3 experiments with at least 9
animals per group (median 6 s.e.m; *P, 0.05). (b) There was no significant difference in total number of CD81 T lymphocytes in tumor-bearing mice
compared to mice from control group. There was significant decrease in cytotoxic capacity of CD81 T cells derived from spleens of tumor-bearing hMSC
treatedmice. Combined results of 3 experiments with at least 9 animals per group (median6 s.e.m.; *P, 0.05). (c) There was no significant difference in
total number of CD32NKp461 NKcells in tumor-bearingmice compared tomice from control group. Therewas significant decrease in cytotoxic capacity
of CD32NKp461NKcells derived from spleens of tumor-bearing hMSC treatedmice. Combined results of 3 experiments with at least 9 animals per group
(median 6 s.e.m.; *P , 0.05).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2298 | DOI: 10.1038/srep02298 4
Figure 3 | hMSC downregulated NKT-like cells and increase number of T regulatory cells. (a) There was significant decrease in percentage
and total number (b) of CD31NKp461 NKT-like cells in spleens of tumor-bearing mice that received hMSC. Isotype controls (c) and representative
dotplots (d) confirm significant decrease in percentage of NKT cells in spleens of hMSC treated mice. Combined results of 4 experiments with at least 9
animals per group (mean 6 s.e.m.; *P, 0.05). (e) There was significant increase in both percentage and total number (f) of Foxp31 regulatory cells cells
in spleens of tumor-bearing mice that received hMSC. Representative histogram (g) confirms significant increase in percentage of Foxp31 T regulatory
cells in spleens of hMSC treated mice. Histograms and mean values presented in the graphs are gated on CD41 cells. Combined results of 4 experiments
with at least 9 animals per group (mean 6 s.e.m.; *P , 0.05).
www.nature.com/scientificreports
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found that these cells isolated from tumor-bearing and hMSC-
treated animals showed decreased cytotoxic activity when compared
with cytotoxic activity of splenocytes cells obtained fromnon-treated
tumor-bearing mice. This could be explained by the fact that MSC
can directly impair the function of a variety of immune cells, includ-
ing B andT lymphocytes, dendritic cells, and natural killer cells43,44–46.
In order, to dissect which cell population is responsible for this lower
cytotoxicity, we tested CD81T andNK cytotoxic cells activity in vitro
and found a significant decrease in cytotoxic capacity of both cells
types in tumor-bearing hMSC-treated animals. NK-cell function is
controlled by a variety of mechanisms, some of which are used by
MSC tomediate NK-cell inhibition47.With respect to soluble factors,
in vitro studies have shown that MSC, without or after stimulation,
secrete a wide range of regulating molecules48, including IL-15, TGF-
b1, and PGE2 and have the potential to affect NK-cell cytotoxicity
and cytokine production49. Also, MSC have a profound inhibitory
effect on activation of T cells, which affects both naive and memory
T cells and is manifested in antigen-specific proliferation, IFN-c
Figure 4 | hMSC stimulated production of Th2 and inhibited production of Th1 cytokines in tumor-bearing mice. (a) Measurement of cytokines
in serum. The level of TGF-b, IL-10 and IL-4 was significantly lower and level of IFN-c was significantly higher in serum samples of tumor-bearing
animals that received hMSC compared to tumor-bearing animals that were not treated with hMSC. Combined results of 4 experiments with at least 9
animals per group (mean 6 s.e.m.; *P, 0.05; **P, 0.01). (b)Measurement of intracellular production of cytokines. There was significant difference in
total number of IL-10 producing CD41 splenocytes between hMSC treated and control tumor-bearing or healthy animals but no difference between
groups in the total number of IFN-c producing cells. The ratio between IL-10 and IFN-c producing CD41 splenocytes was significantly higher in tumor-
bearing animals that received hMSC. Combined results of 4 experiments with 4 animals per group (median 6 s.e.m.; *P , 0.05; **P , 0.01).
www.nature.com/scientificreports
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production, and cytotoxic activity43. Therefore, our findings are con-
sistent with other studies43,44 demonstrating that MSC treatment
mediates T-cell inhibition, suppression of NK-cell proliferation,
cytokine secretion, and cytotoxicity.
MSCwere shown to exert immune protection andmay affect anti-
tumor immunity, and in case of breast cancer, MSC can support
cancer growth5. NKT cells play an important role in anti-tumor
immunity. The anti-tumor potential of NKT cells has been demon-
strated in numerous models of cancer50 and a selective decrease of
number of NKT cells and/or functional activity has been reported in
patients with diverse types of cancer51,52. A recent study demon-
strated that low levels of circulating NKT cells predict a poor clinical
outcome in patients with head and neck squamous cell carcinoma53.
In contrary another study showed that MSC confer immune protec-
tion of cancer cells trough the generation of FoxP31 Tregs28. In this
regard, we estimated percentage and number of CD31NKp461
NKT-like cells and CD41Foxp31 T regulatory cells by multicolor
cytometry. Tumor-bearing animals that received hMSC have a sig-
nificantly lower percentage and number of CD31NKp461 NKT-like
cells but CD41Foxp31 T regulatory cells were more numerous in
tumor-bearing hMSC-treated animals. Studies suggest that Tregs
play a role in the MSC-mediated effects on components of the
immune system that normally serve to eliminate cancer cells28,54.
The role of Tregs in MSC-induced immunomodulation is contro-
versial16,43. We hypothesize that, despite the short time of hMSC
engraftment into tumor, blood, lymph node, spleen, and lung sam-
ples, but long in the liver, these cells are capable of initiating an active
immunomodulating process by interacting with the resident T cell
population favoring the generation of CD41Foxp31 T regulatory
cells similar to that MSC protect breast cancer cells promoting graft
tolerance by increased level of Tregs55.
The mechanism of immunosuppression, especialy cytokine invol-
ment, is critical to further understanding of the findings of our study.
Therefore we quantitated serum levels of IL-4, IL-10, TGF-b and
IFN-c. It is known that MSC are a major source of TGF-b and its
immunosuppressive properties generate polarization away from a
Th1 phenotype toward to Th2 phenotype28. The observed increase
in levels of IL-4, IL-10, TGF-b and decreased level of IFN-c favors the
argument for aberrant activation of the Th2 response. Additionally,
we found a clear difference in the number of IL-10 producing CD41
cells in spleens of hMSC-treated animals mice when compared to
tumor-bearing or control group which was not accompanied by
different number of IFN-c producing CD41 splenocytes cells.
Interestingly, when we calculated ratio of IL-10 vs. IFN-c in indi-
vidual animals and compared tumor-bearing animals that received
hMSC and tumor-bearing or control animals, the ratios were higher
in tumor-bearing animals that received hMSC. Recently, Batten
et al.56 demonstrated that co-culture of T cells with MSC completely
change the cytokine profile of T cells decreasing production of IFN-c,
IL-1a and TNFa increasing Th2 cytokines such as IL-10, IL-5, and
IL-13 confirming the fact that MSC create an immunosuppressive
environment that promotes tumor growth.
In conclusion, the findings presented herein indicate that hMSC
stimulated sufficient production of Th2 cytokines promoting the
development of both primary and metastatic tumors by increased
CD41Foxp31 Tregs cells. We demonstrated that hMSC treatment
could play very important roles in tumor progression and therefore
further investigations are needed to explore the long-term biological
effects of hMSC for the breast cancer patients.
Methods
Experimental animals. Female BALB/c mice (obtained from the Military Medical
Academy Belgrade, Serbia) 8–10 weeks old, were used for this study. All of the animal
procedures were subjected to review and approval by the Ethics Committee of
Medical Faculty, Kragujevac which also complies with the National Institutes of
Health (NIH) guidelines for humane treatment of laboratory animals.
Cell lines and cell culture techniques. The mouse breast tumour cells line 4T1 was
purchased from American Type Culture Collection (ATCC, Manassas, VA). Briefly,
the cells were cultured in 25 mL tissues culture flasks (BD Falcon) in high glucose
DMEM (Sigma, UK) supplemented with 10% heat-inactivated fetal bovine serum
(FBS), 2 mM glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin (Sigma,
UK) at 37uC in humidified atmosphere containing 5% CO2.
Isolation and expansion of human mesenchymal stem cells (hMSC).HumanMSC
were isolated from mononuclear peripheral blood cells using the methodology
described by Trivanovic et al.57, and under in vitro conditions showing a multipotent
capacity to differentiate along mesenchymal lineages (osteogenic, chondrogenic,
adipogenic, and myogenic). In addition, they were fully characterized and displaying
a normal karyotype. hMSC were cultured in DMEM supplemented by 10% FBS, a-
MEM and antibiotics (penicillin 100 U/mL, streptomycin 100 mg/mL; Hyclone,
Logan, UT) at 37uC in a humidified atmosphere containing 95% air and 5%CO2. The
culture medium was changed every 3 days.
Tumour challenge and tumor volume. Mice were divided into four groups. Two
groups of BALB/cmice were injected with 50 ml of a single-cell suspension containing
23 104 4T1mammary carcinoma cells in 50 ml of PBS, orthotopically into the fourth
mammary fat-pad of mice (direct injection in the same flank on each mouse). One of
these groups was transplanted with 4 3 105 hMSC in 100 ml of PBS intravenously by
tail vein injection on the same day (4T1 1 hMSC group). Group 3 received 4 3
105 hMSC in 100 ml of PBS intravenously by tail vein injection only (hMSC group);
and group 4was used as a control (no any treatment). Tumor volumes were calculated
according to the following formula: tumor volume (mm3) 5 L 3 W2/2, where L
represents the major axis (largest cross sectional diameter) of the tumor while W
represents minor axis58. The data were presented as mean 6 standard error of mean
(mean 6 s.e.m.).
Detection of engrafted human MSC: DNA extraction and polymerase chain
reaction (PCR) analysis. The biological samples were submitted to DNA extraction
and PCR analysis to detect the presence of human genes in mice recipients. Genomic
DNA for PCR analysis was prepared from tissues (peripheral blood, lymph node,
spleen, liver, lung and tumor) using the KAPA Express Extract (Kapabiosystems,
Boston, Massachusetts, USA). Amplifications were performed using the KAPA2G
RobustHotStart ReadyMix (Kapabiosystems). Amplification of humanCYP1A1 gene
was used for detection of human DNA in each sample of mouse tissue after DNA
extraction. Endogenousmouse b-actin gene was also amplified, as an internal control.
The primers for human CYP1A1 gene were: forward primer 5’ GAA CTG CCA CTT
CAG CTG TCT 3’ and reverse primer: 5’ CAG CTG CAT TTG GAA GTG CTC 3’.
The primers for b-actin gene were: sense primer 5’ GGACCTGACAGACTACC 3’
and antisense primer 3’GGCATAGAGGTCTTTACGG. Also, human DNA was
isolated from MSC culture and used as positive controls.
Immunocytochemistry. Immunocytochemistry was performed to explore the
presence of hMSC in the liver and lung of mice with intravenously administered
hMSC. The tissues were routinely fixed in 4% buffered formaldehyde, dehydrated
through graded alcohols, cleared in xylene, and subsequently embedded in paraffin.
The paraffin-embedded tissue samples were sectioned at 4–5 mm, then deparaffinized
by two 10 min washes in xylene and rehydrated in a series of 100%, 96%, 70% and
50% alcohol. Immunohistochemical staining was performed by the streptavidin-
biotin method. Briefly, sections were deparaffinized and incubated with 3% hydrogen
peroxide to block endogenous peroxidase activity. The sections were microwaved for
20 min in 10 mmol/L sodium citrate (pH 6.0) and incubated withmousemonoclonal
IgG1 antibody clone 113-1 targeting a 65 kD protein on the surface of intact human
mitochondria (MAB-12730, Millipore) 60 minutes, respectively. After the primary
antibody, biotinylated secondary antibodies were applied, followed by detection using
the ABC (Avidin-Biotin peroxidase Complex) method. Diaminobenzidine was used
as the chromogen. Light counterstaining was performed with haematoxylin. Negative
controls were obtained using an irrelevant antibody instead of the primary antibody.
The slides were examined by conventional light microscopy.
Histopathological analysis. Paraffin-embedded mouse extracted organs sections
(sectioned into 4 mm slides ) were prepared by a routine procedure. The sections were
stained with hematoxylin-eosin (HE) by standard protocol.
The fixed lungs and livers were examined under low-power (x100) light micro-
scopy (Zeiss Axioskop 40, Jena, Germany) equipped with digital camera. Images were
captured in a computer and the surface areas of themetastatic regions were measured
using Autodesk AutoCAD 2012 software application for design and drafting. Briefly,
the area of whole tissue section was marked as A and the area of each of metastatic
areas as B, and the surface of each specified areas was measured, and presented in
Autodesk AutoCAD program as unitless number. The metastatic lesion was assessed
in each section as the percentage of tissue parenchyma with metastasis by using the
following formula: N 5 Bt 3 100/At where N represents the percentage (%) of
metastatic area in the whole tissue section, At (A total) is the sum of areas of the whole
tissue section (At5A11A21….An), Bt (B total) is the sum ofmetastatic regions in
the whole tissue section (Bt 5 B1 1 B2 1 ….Bm).
Estimation of serum levels of IL-4, IL-10, TGF-b and IFN-c cytokines. The
cytokine production level in mouse serum was analyzed for all three inoculated and
one control group using peripheral blood. The serum samples were used to quantitate
www.nature.com/scientificreports
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the serum levels of IL-4, IL-10, TGF-b, and IFN-c. Levels of these cytokines were
determined by commercially available enzyme-linked immunosorbent assay (ELISA)
kits (R&D Systems Minneapolis, MN), which were specific for mouse cytokines and
used according to the manufacturer’s instructions.
Cellular analysis of spleens. Thirty five days after 4T1 tumor cells injection, mice
were sacrificed and single-cell suspensions from spleen were obtained by mechanical
dispersion through a cell strainer (BD Pharmingen, USA) in complete growth
medium. Additionally, erythrocytes from spleen were removed using lysing solution
(BD Pharmingen). After three washes, cells were resuspended in complete growth
medium.
Flow cytometric analysis. Single-cell suspensions of spleens were incubated with
mAbs specific for mouse CD3, CD4, CD8, CD25, and NKp46 (BD Pharmingen-
eBioscience). Appropriate isotype control antibodies were used to assess the level of
specific labeling. Dead cells were excluded by gating out propidium iodide-positive
cells. The gate used for FACS analysis was the mononuclear cell region in the forward
scatter-side scatter (FSC-SSC) plot. For intracellular staining of Foxp3, cells were
fixed and permeabilized with permeabilization buffer (BD Pharmingen).
Permeabilized cells were stained with anti-mouse Foxp3 mAbs (BD Pharmingen).
Stained cells were analyzed subsequently using a FACSAria instrument (BD). Data
were analyzed using CELLQUEST software and DiVa (BD).
Intracellular cytokine staining. Single cell suspensions of spleens were stimulated
with Phorbol 12-myristate 13-acetate (50 ng/ml) (Sigma, USA) and Ionomycin
(Sigma, USA) (500 ng/ml) with GolgyStop (BD Pharmingen), and incubated 4 hours
at 37uC, 5% CO2. Cells were stained with anti-CD4mAb or isotype-matched control.
Subsequently, cells were fixed, permeabilized and intracellular staining was done
using anti-IL-10 and anti-IFN-c mAb (BD Pharmingen) and analyzed by flow
cytometry.
NK cell and CD81 FFT cell separation. NK cells were isolated from spleen cells by
magnetic cell sorting. Single-cell suspensions of splenocytes were labeled using
microBeads conjugated to monoclonal anti-mouse CD49b (DX5) antibodies
(Miltenyi Biotec) and positively selected using MidiMACS separator (Miltenyi
Biotec). CD49b labeled cells that retained in the magnetic column were highly
enriched NK cells, and were used in the cytotoxicity study as purified NK cells. In
addition, CD81 T cells were negatively selected from single-cell suspensions of
splenocytes using aDynalmouse T cell negative isolation kit (Invitrogen) which
depletes B cells, NK cells, monocytes/macrophages, dendritic cells (DCs),
granulocytes, and erythrocytes using a mixture of rat mAbs for mouse CD45R,
CD11b, Ter-119, and CD16/32. Cell suspensions containing CD8 T cells were then
used in the cytotoxicity assays.
Cytotoxicity assays. Cytotoxic activity of splenocytes, enriched NK cells and
enriched CD81 T cells was measured using the 4 h MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide assay (Sigma) at various target-effector (T:E)
ratios. 4T1mouse breast tumor cells were used as targets. The percentage of cytotoxity
was calculated as: cytotoxity (%) 5 [1-(experimental group (OD)/control group
(OD)] 3 100. Data were expressed as the mean of triplicate wells 6 SEM. Cytotoxic
activity was also presented by lytic units, LU20/107 cells, calculated from means of
triplicates percentages of killing obtained in four different T:E ratios59.
Statistical analysis.All data were expressed asmean6 s.e.m. Statistical analysis of the
data was performed using statistical package SPSS, version 13. Comparison between
groups was made using one-way ANOVA, or nonparametric Mann-Whitney Rank
Sum and Kruskal-Wallis tests. P, 0.05 was considered significant and P, 0.01 was
highly significant.
1. Meirelles, D. L., Chagastelles, P. C. & Nardi, N. B. Mesenchymal stem cells reside
in virtually all post-natal organs and tissues. J Cell Sci. 119, 2204–2213 (2006).
2. Pittenger, M. F. et al. Multilineage potential ofadult human mesenchymal stem
cells. Science. 284, 143–147 (1999).
3. Stagg, J. Mesenchymal stem cells in cancer. Stem Cell Rev. 4, 119–124 (2008).
4. Roorda, B. D., Ter Elst, A., Kamps, W. A. & de Bont, E. S. Bone marrow-derived
cells and tumor growth: contribution of bone marrow-derived cells to tumor
micro-environments with special focus on mesenchymal stem cells. Crit Rev
Oncol Hematol. 69, 187–198 (2009).
5. Li,n S. Y. et al. The isolation of novel mesenchymal stromal cell chemotactic
factors from the conditionedmedium of tumor cells. Exp Cell Res. 314, 3107–3117
(2008).
6. Uccelli, A., Moretta, L. & Pistoia, V.Mesenchymal stem cells in health and disease.
Nat Rev. 8, 726–736 (2008).
7. Ramasamy, R., Lam, E. W., Soeiro, I., Tisato, V., Bonnet, D. & Dazzi, F.
Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact
on in vivo tumor growth. Leukemia. 21, 304–310 (2007).
8. Yu, J. M., Jun, E. S. & Bae, Y. C. Mesenchymal stem cells derived from human
adipose tissues favour tumor cell growth in vivo. Stem Cells Dev. 17, 463–473
(2008).
9. Kucerova, L., Matuskova, M., Hlubinova, K., Altanerova, V. & Altaner, C. Tumor
cell behaviour modulation by mesenchymal stromal cells. Mol Cancer. 9, 1–15
(2010).
10. Secchiero, P. et al. Human bone marrow mesenchymal stem cells display anti-
cancer activity in SCID mice bearing disseminated non-Hodgkin’s lymphoma
xenografts. Plos One. 16, 5–6 (2010).
11. Ling, X. et al. Mesenchymal Stem Cells Overexpressing IFN-b Inhibit Breast
Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor
Model. Cancer Microenviron. 3, 83–95 (2010).
12. Rasmusson, I., Ringden, O., Sundberg, B. & Le Blanc, K. Mesenchymal stem cells
inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T
lymphocytes or natural killer cells. Transplantation. 76, 1208–1213 (2003).
13. Raffaghello, L. et al. Humanmesenchymal stem cells inhibit neutrophil apoptosis:
a model for neutrophil preservation in the bone marrow niche. Stem Cells. 26,
151–162 (2008).
14. Djouad, F. et al. Immunosuppressive effect of mesenchymal stem cells favors
tumor growth in allogeneic animals. Blood. 102, 3837–3844 (2003).
15. Ning, H. et al. The correlation between cotransplantation of mesenchymal stem
cells and higher recurrence rate in hematologic malignancy patients: outcome of a
pilot clinical study. Leukemia. 22, 593–599 (2008).
16. Aggarwal, S. & Pittenger, M. F. Human mesenchymal stem cells modulate
allogeneic immune cell responses. Blood. 105, 1815–1822 (2005).
17. Selmani, Z. et al. Human leukocyte antigen-G5 secretion by humanmesenchymal
stem cells is required to suppress T lymphocyte and natural killer function and to
induce CD4 1 CD25 high FOXP31 regulatory T cells. Stem Cells. 26, 212–222
(2008).
18. Fernandez, M. A. et al. T regulatory cells contribute to the attenuated primary
CD81 and CD41 T cell responses to herpes simplex virus type 2 in neonatal
mice. J Immunol. 180, 1556–1564 (2008).
19. Vasir, B. et al. Fusions of dendritic cells with breast carcinoma stimulate the
expansion of regulatory T cells while concomitant exposure to IL-12, CpG
oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated
tumor reactive cells. J Immunol. 181, 808–821 (2008).
20. Studeny, M. et al. Mesenchymal stem cells: potential precursors for tumor
stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst. 96,
1593–1603 (2004).
21. Annacker, O. et al. A CD25 1 CD41 T cells regulate the expansion of peripheral
CD4 T cells through the production of IL-10. J Immunol. 166, 3008–3018 (2001).
22. Awasthi, A. et al. A dominant function for interleukin 27 in generating interleukin
10-producing anti-inflammatory T cells. Nat Immunol. l8, 1380–1389 (2007).
23. Ammirante, M., Luo, J. L., Grivennikov, S., Nedospasov, S. & Karin, M. B-cell
derived lymphotoxin promotes castration-resistant prostate cancer. Nature. 464,
302–305 (2010).
24. Rafei, M. et al. A granulocyte-macrophage colony-stimulating factor and
interleukin-15 fusokine induces a regulatory B cell population with immune
suppressive properties. Nat Med. 15, 1038–1045 (2009).
25. Carpentier, A. F. & Meng, Y. Recent advances in immunotherapy for human
glioma. Curr Opin Oncol. 18, 631–636 (2006).
26. Lizee, G., Radvanyi, L. G., Overwijk, W. W. & Hwu, P. Improving antitumor
immune responses by circumventing immunoregulatory cells and mechanisms.
Clin Cancer Res. 12, 4794–4803 (2006).
27. Olkhanud, P. B. et al. Tumor-Evoked Regulatory B Cells Promote Breast Cancer
Metastasis by Converting Resting CD41 T Cells to T-Regulatory Cells. Cancer
Res. 71, 3505–3515 (2011).
28. Patel, S. A. et al. Mesenchymal stem cells protect breast cancer cells through
regulatory T cells: role of mesenchymal stem cell-derived TGF-beta. J Immunol.
184, 5885–5894 (2010).
29. Oreffo, R. O., Cooper, C., Mason, C. & Clements, M. Mesenchymal stem cells:
lineage, plasticity, and skeletal therapeutic potential. Stem Cell Rev. 1, 169–178
(2005).
30. Parekkadan, B. et al. Immunomodulation of activated hepatic stellate cells by
mesenchymal stem cells. Biochem Biophys Res Commun. 363, 247–252 (2007).
31. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor
stroma generation and woundhealing. N Engl J Med. 315, 1650–1659 (1986).
32. Karnoub, A. E. et al. Mesenchymal stem cells within tumour stroma promote
breast cancer metastasis. Nature. 449, 557–563 (2007).
33. Studeny, M. et al. Bone marrow-derived mesenchymal stem cells as vehicles for
interferon-beta delivery into tumors. Cancer Res. 62, 3603–3608 (2002).
34. Kidd, S. et al. Direct evidence of mesenchymal stem cell tropism for tumor and
wounding microenvironments using in vivo bioluminescent imaging. Stem Cells.
27, 2614–2623 (2009).
35. Lin, Y. T. et al. Human mesenchymal stem cells prolong survival and ameliorate
motor deficit through trophic support in Huntington’s disease mouse models.
Plos One. 6, 8–e22924 (2011).
36. Eggenhofer, E. et al. Mesenchymal stem cells are short-lived and do not migrate
beyond the lungs after intravenous infusion. Front Immunol. 3, 297 (2012).
37. Khakoo, A. Y. et al. Humanmesenchymal stem cells exert potent antitumorigenic
effects in a model of Kaposi’s sarcoma. J Exp Med. 203, 1235–1247 (2006).
38. Li, G. C. et al. Human mesenchymal stem cells inhibit metastasis of a
hepatocellular carcinoma model using the MHCC97-H cell line. Cancer Sci. 101,
2546–2553 (2010).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2298 | DOI: 10.1038/srep02298 8
39. Ohlsson, L. B., Varas, L., Kjellman, C., Edvardsen, K. & Lindvall, M.Mesenchymal
progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin
matrix. Exp Mol Pathol. 75, 248–255 (2003).
40. Wang, H. et al. Trafficking mesenchymal stem cell engraftment and
differentiation in tumor-bearing mice by bioluminescence imaging. Stem Cells.
27, 1548–1558 (2009).
41. Djouad, F. et al. Earlier onset of syngeneic tumors in the presence of mesenchymal
stem cells. Transplantation. 82, 1060–1066 (2006).
42.Muehlberg, F. L. et al. Tissue resident stem cells promote breast cancer growth and
metastasis. Carcinogenesis. 30, 589–597 (2009).
43. Krampera, M. et al. Bone marrow mesenchymal stem cells inhibit the response of
naive and memory antigen-specific T cells to their cognate peptide. Blood. 101,
3722–3729 (2003).
44. Rutella, S., Danese, S. & Leone, G. Tolerogenic dendritic cells: Cytokine
modulation comes of age. Blood. 108, 1435–1440 (2006).
45. Corcione, A. et al. Human mesenchymal stem cells modulate B-cell functions.
Blood. 107, 367–372 (2006).
46. Sotiropoulou, P. A., Perez, S. A., Gritzapis, A. D., Baxevanis, C. N. & Papamichail,
M. Interactions between human mesenchymal stem cells and natural killer cells.
Stem Cells. 24, 74–85 (2006).
47. Spaggiari, G. M. et al. Mesenchymal stem cells inhibit natural killer-cell
proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-
dioxygenase and prostaglandin E2. Blood. 111, 1327–1333 (2008).
48. Minguell, J. J., Erices, A. & Conget, P. Mesenchymal stem cells. Exp Biol Med. 226,
507–520 (2001).
49. Joshi, P. C., Zhou, X., Cuchens,M. & Jones, Q. Prostaglandin E2 suppressed IL-15-
mediated human NK cell function through down-regulation of common c-chain.
J Immunol. 166, 885–891 (2001).
50. Swann, J., Crowe, N. Y., Hayakawa, Y., Godfrey, D. I. & Smyth, M. J. Regulation
of antitumour immunity by CD1d-restricted NKT cells. Immunol Cell Biol. 82,
323–331 (2004).
51. Yanagisawa, K. et al. Impaired proliferative response of V alpha 24NKT cells from
cancer patients against alpha-galactosylceramide. J Immunol. 168, 6494–6499
(2002).
52. Dhodapkar, M. V. et al. A reversible defect in natural killer T cell function
characterizes the progression of premalignant to malignant multiple myeloma.
J Exp Med. 197, 1667–1676 (2003).
53. Molling, J. W. et al. Low levels of circulating invariant natural killer T cells predict
poor clinical outcome in patients with head and neck squamous cell carcinoma.
J Clin Oncol. 25, 862–868 (2007).
54. Ghiringhelli, F., Me´nard, C., Martin, F. & Zitvogel, L. The role of regulatory T cells
in the control of natural killer cells: relevance during tumor progression. Immunol
Rev. 214, 229–238 (2006).
55. Casiraghi, F. et al. Pretransplant infusion of mesenchymal stem cells prolongs the
survival of a semiallogeneic heart transplant through the generation of regulatory
T cells. J Immunol. 181, 3933–3946 (2008).
56. Batten, P. et al. Human mesenchymal stem cells induce T cell anergy and
downregulate T cell alloresponses via the TH2 pathway: relevance to tissue
engineering human heart valves. Tissue Eng. 12, 2263–2273 (2006).
57. Trivanovic, D. et al. Mesenchymal stem cells isolated from peripheral blood and
umbilical cord Wharton’s jelly. Srp Arh Celok Lek. 141, 178–186 (2013).
58. Carlsson, G., Ekelund, E., Stigsson, L. & Hafstrom, L. Vascularization and
tumour volume estimations of solitary liver tumours in rats. Ann Chir Gynaecol.
72, 187–191 (1983).
59. Jonjic, B. M. et al. Innate direct anticancer effector function of human immature
dendritic cells. I. Involvement of an apoptosis-inducing pathway. J Immunol. 168,
1823–1830 (2002).
Acknowledgements
This work was supported by grants from the SerbianMinistry of Science and Technological
Development (ON175103 and ON175069), Serbia and Faculty of Medicine, University of
Kragujevac, Serbia (Grant no. JP 15/10). We thank Dr. Nada Pejnovic for critical review of
the manuscript and Miljan Nedeljkovic for excellent technical assistance.
Author contributions
N.A., M.L.L., M.S. and B.Lj. conceived the study and designed the experiments; B.Lj., M.M.,
V.V., B.M., D.B. and S.P. performed the experiments; B.Lj., M.M., V.V., N.A., M.L.L. and
M.S. analyzed the data; B.Lj. wrote themanuscript, and all authors reviewed themanuscript.
Additional information
Supplementary information accompanies this paper at http://www.nature.com/
scientificreports
Competing financial interests: The authors declare no competing financial interests.
How to cite this article: Ljujic, B. et al. Human mesenchymal stem cells creating an
immunosuppressive environment and promote breast cancer in mice. Sci. Rep. 3, 2298;
DOI:10.1038/srep02298 (2013).
This work is licensed under a Creative Commons Attribution-
NonCommercial-NoDerivs 3.0 Unported license. To view a copy of this license,
visit http://creativecommons.org/licenses/by-nc-nd/3.0
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 3 : 2298 | DOI: 10.1038/srep02298 9
